{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T20:07:41Z","timestamp":1772827661373,"version":"3.50.1"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100002428","name":"Austrian Research Fund\/FWF","doi-asserted-by":"publisher","award":["F3506"],"award-info":[{"award-number":["F3506"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002428","name":"Austrian Research Fund\/FWF","doi-asserted-by":"publisher","award":["W1232"],"award-info":[{"award-number":["W1232"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010001","name":"Federal Office of Public Health","doi-asserted-by":"publisher","award":["16.921318"],"award-info":[{"award-number":["16.921318"]}],"id":[{"id":"10.13039\/100010001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001822","name":"Austrian Academy of Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001822","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.neuropharm.2018.12.032","type":"journal-article","created":{"date-parts":[[2019,1,2]],"date-time":"2019-01-02T11:40:34Z","timestamp":1546429234000},"page":"199-209","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Stereochemistry of phase-1 metabolites of mephedrone determines their effectiveness as releasers at the serotonin transporter"],"prefix":"10.1016","volume":"148","author":[{"given":"Felix P.","family":"Mayer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Cintulova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorothea A.","family":"Pittrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurin","family":"Wimmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dino","family":"Luethi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marion","family":"Holy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathrin","family":"Jaentsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonja","family":"Tischberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guenter","family":"Gmeiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6510-6250","authenticated-orcid":false,"given":"Marius C.","family":"Hoener","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1765-9659","authenticated-orcid":false,"given":"Matthias E.","family":"Liechti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marko D.","family":"Mihovilovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1339-7444","authenticated-orcid":false,"given":"Harald H.","family":"Sitte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2018.12.032_bib1","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/qjmed\/hcs219","article-title":"Analysis of anonymous pooled urine from portable urinals in central London confirms the significant use of novel psychoactive substances","volume":"106","author":"Archer","year":"2013","journal-title":"QJM"},{"key":"10.1016\/j.neuropharm.2018.12.032_bib2","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3109\/15563650.2014.885982","article-title":"Trend analysis of anonymised pooled urine from portable street urinals in central London identifies variation in the use of novel psychoactive substances","volume":"52","author":"Archer","year":"2014","journal-title":"Clin. Toxicol."},{"key":"10.1016\/j.neuropharm.2018.12.032_bib3","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/npp.2015.260","article-title":"Abuse of new psychoactive substances: threats and solutions","volume":"41","author":"Baumann","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2018.12.032_bib4","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1038\/npp.2011.304","article-title":"The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue","volume":"37","author":"Baumann","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2018.12.032_bib5","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/dta.1686","article-title":"The new drug phenomenon","volume":"6","author":"Brandt","year":"2014","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.neuropharm.2018.12.032_bib6","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/j.1471-4159.2011.07339.x","article-title":"Cytochrome P450 mediates dopamine formation in the brain in vivo","volume":"118","author":"Bromek","year":"2011","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2018.12.032_bib7","doi-asserted-by":"crossref","first-page":"5563","DOI":"10.1021\/es5060429","article-title":"Wastewater analysis to monitor spatial and temporal patterns of use of two synthetic recreational drugs, ketamine and mephedrone, in Italy","volume":"49","author":"Castiglioni","year":"2015","journal-title":"Environ. Sci. Technol."},{"key":"10.1016\/j.neuropharm.2018.12.032_bib8","doi-asserted-by":"crossref","first-page":"13009","DOI":"10.1038\/s41598-017-12581-3","article-title":"A new approach towards biomarker selection in estimation of human exposure to chiral chemicals: a case study of mephedrone","volume":"7","author":"Castrignano","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2018.12.032_bib9","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0169-328X(02)00177-8","article-title":"Constitutive expression and localization of the major drug metabolizing enzyme, cytochrome P4502D in human brain","volume":"103","author":"Chinta","year":"2002","journal-title":"Brain Res. Mol. Brain Res."},{"key":"10.1016\/j.neuropharm.2018.12.032_bib10","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0014-2999(99)00538-5","article-title":"Inhibition of plasma membrane monoamine transporters by beta-ketoamphetamines","volume":"381","author":"Cozzi","year":"1999","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.12.032_bib11","doi-asserted-by":"crossref","first-page":"16928","DOI":"10.1523\/JNEUROSCI.2502-11.2011","article-title":"Genetic deletion of trace amine 1 receptors reveals their role in auto-inhibiting the actions of ecstasy (MDMA)","volume":"31","author":"Di Cara","year":"2011","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2018.12.032_bib12","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1016\/j.bcp.2013.04.004","article-title":"Substituted methcathinones differ in transporter and receptor interactions","volume":"85","author":"Eshleman","year":"2013","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.12.032_bib13","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.tips.2011.08.005","article-title":"Cytochrome P450 enzymes in the brain: emerging evidence of biological significance","volume":"32","author":"Ferguson","year":"2011","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2018.12.032_bib14","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1111\/bph.12628","article-title":"The preclinical pharmacology of mephedrone; not just MDMA by another name","volume":"171","author":"Green","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.12.032_bib15","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1111\/bph.12951","article-title":"Stereochemistry of mephedrone neuropharmacology: enantiomer-specific behavioural and neurochemical effects in rats","volume":"172","author":"Gregg","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.12.032_bib16","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1124\/jpet.111.184119","article-title":"4-Methylmethcathinone (mephedrone): neuropharmacological effects of a designer stimulant of abuse","volume":"339","author":"Hadlock","year":"2011","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2018.12.032_bib17","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/S0140-6736(16)30258-6","article-title":"Mephedrone use is increasing in London","volume":"387","author":"Hockenhull","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2018.12.032_bib18","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.euroneuro.2015.12.010","article-title":"Abuse-related neurochemical and behavioral effects of cathinone and 4-methylcathinone stereoisomers in rats","volume":"26","author":"Hutsell","year":"2016","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2018.12.032_bib19","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/clpt.2011.78","article-title":"The norepinephrine transporter inhibitor reboxetine reduces stimulant effects of MDMA (\"ecstasy\") in humans","volume":"90","author":"Hysek","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2018.12.032_bib20","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1111\/j.1476-5381.2012.01936.x","article-title":"Carvedilol inhibits the cardiostimulant and thermogenic effects of MDMA in humans","volume":"166","author":"Hysek","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.12.032_bib21","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1177\/0269881116653106","article-title":"Mephedrone and 3,4-methylenedioxy-methamphetamine: comparative psychobiological effects as reported by recreational polydrug users","volume":"30","author":"Jones","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2018.12.032_bib22","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3109\/00952990.2011.643999","article-title":"\"Bath salt\" ingestion leading to severe intoxication delirium: two cases and a brief review of the emergence of mephedrone use","volume":"38","author":"Kasick","year":"2012","journal-title":"Am. J. Drug Alcohol Abuse"},{"key":"10.1016\/j.neuropharm.2018.12.032_bib23","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1111\/j.1476-5381.2011.01499.x","article-title":"Mephedrone, compared with MDMA (ecstasy) and amphetamine, rapidly increases both dopamine and 5-HT levels in nucleus accumbens of awake rats","volume":"164","author":"Kehr","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.12.032_bib24","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/dta.313","article-title":"Cathinone derivatives: a review of their chemistry, pharmacology and toxicology","volume":"3","author":"Kelly","year":"2011","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.neuropharm.2018.12.032_bib25","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1007\/s00213-017-4610-0","article-title":"Dreamlike effects of LSD on waking imagery in humans depend on serotonin 2A receptor activation","volume":"234","author":"Kraehenmann","year":"2017","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2018.12.032_bib26","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1124\/pr.108.000869","article-title":"SLC6 neurotransmitter transporters: structure, function, and regulation","volume":"63","author":"Kristensen","year":"2011","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuropharm.2018.12.032_bib27","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0893-133X(99)00148-7","article-title":"Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, \"Ecstasy\") are attenuated by the serotonin uptake inhibitor citalopram","volume":"22","author":"Liechti","year":"2000","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2018.12.032_bib28","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1124\/jpet.107.132647","article-title":"Trace amine-associated receptor 1 modulates dopaminergic activity","volume":"324","author":"Lindemann","year":"2008","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2018.12.032_bib29","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/ijnp\/pyy047","article-title":"Monoamine transporter and receptor interaction profiles in vitro predict reported human doses of novel psychoactive stimulants and psychedelics","volume":"21","author":"Luethi","year":"2018","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2018.12.032_bib30","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.neuropharm.2017.07.026","article-title":"Pharmacological profile of mephedrone analogs and related new psychoactive substances","author":"Luethi","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2018.12.032_bib31","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.neuropharm.2017.07.012","article-title":"Monoamine receptor interaction profiles of 4-thio-substituted phenethylamines (2C-T drugs)","volume":"134","author":"Luethi","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2018.12.032_bib32","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.euroneuro.2011.07.009","article-title":"Interaction of mephedrone with dopamine and serotonin targets in rats","volume":"22","author":"Martinez-Clemente","year":"2012","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2018.12.032_bib33","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1111\/bph.13547","article-title":"Phase I metabolites of mephedrone display biological activity as substrates at monoamine transporters","volume":"173","author":"Mayer","year":"2016","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.12.032_bib34","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/7854_2016_63","article-title":"Application of a combined approach to identify new psychoactive street drugs and decipher their mechanisms at monoamine transporters","volume":"32","author":"Mayer","year":"2017","journal-title":"Curr. Top Behav. Neurosci."},{"key":"10.1016\/j.neuropharm.2018.12.032_bib35","first-page":"406","article-title":"Drug-metabolizing cytochrome P450s in the brain","volume":"27","author":"Miksys","year":"2002","journal-title":"J. Psychiatry Neurosci."},{"key":"10.1016\/j.neuropharm.2018.12.032_bib36","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.chroma.2012.09.079","article-title":"Chiral separation of new cathinone- and amphetamine-related designer drugs by gas chromatography-mass spectrometry using trifluoroacetyl-l-prolyl chloride as chiral derivatization reagent","volume":"1269","author":"Mohr","year":"2012","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.neuropharm.2018.12.032_bib37","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1124\/jpet.110.166595","article-title":"Endocrine and neurochemical effects of 3,4-methylenedioxymethamphetamine and its stereoisomers in rhesus monkeys","volume":"334","author":"Murnane","year":"2010","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2018.12.032_bib38","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1124\/pr.115.011478","article-title":"Psychedelics","volume":"68","author":"Nichols","year":"2016","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuropharm.2018.12.032_bib39","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1208\/s12248-017-0132-2","article-title":"Pharmacokinetics of mephedrone and its metabolites in human by LC-MS\/MS","volume":"19","author":"Olesti","year":"2017","journal-title":"AAPS J."},{"key":"10.1016\/j.neuropharm.2018.12.032_bib40","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S2215-0366(18)30305-5","article-title":"The growing problem of mephedrone use in Warsaw, Poland, 2010-18","volume":"5","author":"Ordak","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.neuropharm.2018.12.032_bib41","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/7854_2016_61","article-title":"Clinical pharmacology of the synthetic cathinone mephedrone","volume":"32","author":"Papaseit","year":"2017","journal-title":"Curr. Top Behav. Neurosci."},{"key":"10.1016\/j.neuropharm.2018.12.032_bib42","first-page":"1182","article-title":"Serotonin dysfunction in the nucleus accumbens of rats during withdrawal after unlimited access to intravenous cocaine","volume":"274","author":"Parsons","year":"1995","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2018.12.032_bib43","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/0166-4328(96)00101-5","article-title":"Extracellular serotonin is decreased in the nucleus accumbens during withdrawal from cocaine self-administration","volume":"73","author":"Parsons","year":"1996","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2018.12.032_bib44","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/dta.1369","article-title":"In vitro metabolism studies on mephedrone and analysis of forensic cases","volume":"5","author":"Pedersen","year":"2013","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.neuropharm.2018.12.032_bib45","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.drugalcdep.2017.04.024","article-title":"Synthetic cathinones and stereochemistry: S enantiomer of mephedrone reduces anxiety- and depressant-like effects in cocaine- or MDPV-abstinent rats","volume":"178","author":"Philogene-Khalid","year":"2017","journal-title":"Drug Alcohol Depend."},{"issue":"12","key":"10.1016\/j.neuropharm.2018.12.032_bib46","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1021\/acschemneuro.7b00212","article-title":"Stereoselective differences between the reinforcing and motivational effects of cathinone-derived 4-methylmethcathinone (mephedrone) in self-administering rats","volume":"8","author":"Philogene-Khalid","year":"2017","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2018.12.032_bib47","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ejphar.2015.03.004","article-title":"The profile of mephedrone on human monoamine transporters differs from 3,4-methylenedioxymethamphetamine primarily by lower potency at the vesicular monoamine transporter","volume":"755","author":"Pifl","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.12.032_bib48","doi-asserted-by":"crossref","first-page":"8485","DOI":"10.1073\/pnas.1103029108","article-title":"TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity","volume":"108","author":"Revel","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2018.12.032_bib49","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.biopsych.2012.05.014","article-title":"Trace amine-associated receptor 1 partial agonism reveals novel paradigm for neuropsychiatric therapeutics","volume":"72","author":"Revel","year":"2012","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2018.12.032_bib50","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.euroneuro.2016.05.001","article-title":"Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens","volume":"26","author":"Rickli","year":"2016","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2018.12.032_bib51","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s002130051022","article-title":"Self-administration of cocaine analogs by rats","volume":"144","author":"Roberts","year":"1999","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2018.12.032_bib52","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1073\/pnas.89.5.1817","article-title":"The molecular mechanism of \"ecstasy\" [3,4-methylenedioxy-methamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release","volume":"89","author":"Rudnick","year":"1992","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2018.12.032_bib53","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1007\/s00216-015-9247-4","article-title":"Determination of cathinones and other stimulant, psychedelic, and dissociative designer drugs in real hair samples","volume":"408","author":"Salomone","year":"2016","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.neuropharm.2018.12.032_bib54","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s00213-010-2070-x","article-title":"Mephedrone (4-methylmethcathinone; 'meow meow'): chemical, pharmacological and clinical issues","volume":"214","author":"Schifano","year":"2011","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2018.12.032_bib55","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1124\/mol.113.090118","article-title":"Adrenaline rush: the role of adrenergic receptors in stimulant-induced behaviors","volume":"85","author":"Schmidt","year":"2014","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.12.032_bib56","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1124\/mol.67.1.140","article-title":"Amphetamines take two to tango: an oligomer-based counter-transport model of neurotransmitter transport explores the amphetamine action","volume":"67","author":"Seidel","year":"2005","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.12.032_bib57","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/00008571-200104000-00007","article-title":"Cellular localization and regional distribution of CYP2D6 mRNA and protein expression in human brain","volume":"11","author":"Siegle","year":"2001","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.neuropharm.2018.12.032_bib58","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/j.1476-5381.2012.02145.x","article-title":"Pharmacological characterization of designer cathinones in vitro","volume":"168","author":"Simmler","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2018.12.032_bib59","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.tips.2014.11.006","article-title":"Amphetamines, new psychoactive drugs and the monoamine transporter cycle","volume":"36","author":"Sitte","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2018.12.032_bib60","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1046\/j.1471-4159.1998.71031289.x","article-title":"Carrier-mediated release, transport rates, and charge transfer induced by amphetamine, tyramine, and dopamine in mammalian cells transfected with the human dopamine transporter","volume":"71","author":"Sitte","year":"1998","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2018.12.032_bib61","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1046\/j.1471-4159.2000.741317.x","article-title":"Characterization of carrier-mediated efflux in human embryonic kidney 293 cells stably expressing the rat serotonin transporter: a superfusion study","volume":"74","author":"Sitte","year":"2000","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2018.12.032_bib62","first-page":"1043","article-title":"Neurotoxic and pharmacologic studies on enantiomers of the N-methylated analog of cathinone (methcathinone): a new drug of abuse","volume":"279","author":"Sparago","year":"1996","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2018.12.032_bib63","doi-asserted-by":"crossref","first-page":"499","DOI":"10.3109\/15563650.2011.590812","article-title":"Clinical experience with and analytical confirmation of \"bath salts\" and \"legal highs\" (synthetic cathinones) in the United States","volume":"49","author":"Spiller","year":"2011","journal-title":"Clin. Toxicol."},{"key":"10.1016\/j.neuropharm.2018.12.032_bib64","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s00128-016-1869-5","article-title":"The presence of stimulant drugs in wastewater from krakow (Poland): a snapshot","volume":"97","author":"Styszko","year":"2016","journal-title":"Bull. Environ. Contam. Toxicol."},{"key":"10.1016\/j.neuropharm.2018.12.032_bib65","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nrn1008","article-title":"Plasma membrane monoamine transporters: structure, regulation and function","volume":"4","author":"Torres","year":"2003","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2018.12.032_bib66","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/FTD.0000000000000263","article-title":"The toxicology of new psychoactive substances: synthetic cathinones and phenylethylamines","volume":"38","author":"Tyrkko","year":"2016","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.neuropharm.2018.12.032_bib67","first-page":"1233","article-title":"Characterization of an \"in vitro\" blood-brain barrier: effects of molecular size and lipophilicity on cerebrovascular endothelial transport rates of drugs","volume":"247","author":"van Bree","year":"1988","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2018.12.032_bib68","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.neuropharm.2014.11.010","article-title":"Stereochemistry and neuropharmacology of a 'bath salt' cathinone: S-enantiomer of mephedrone reduces cocaine-induced reward and withdrawal in invertebrates","volume":"91","author":"Vouga","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2018.12.032_bib69","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.mibio.2003.09.014","article-title":"Determination of lipophilicity and its use as a predictor of blood-brain barrier penetration of molecular imaging agents","volume":"5","author":"Waterhouse","year":"2003","journal-title":"Mol. Imag. Biol."},{"key":"10.1016\/j.neuropharm.2018.12.032_bib70","series-title":"United Nations Office on Drugs and Crime, World Drug Report 2016","author":"World Drug Report","year":"2016"},{"key":"10.1016\/j.neuropharm.2018.12.032_bib71","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.toxlet.2016.10.012","article-title":"Cooling down the bath salts: carvedilol attenuation of methylone and mephedrone mediated hyperthermia","volume":"263","author":"Zona","year":"2016","journal-title":"Toxicol. Lett."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390818309213?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390818309213?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,11,13]],"date-time":"2019-11-13T06:26:54Z","timestamp":1573626414000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390818309213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":71,"alternative-id":["S0028390818309213"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2018.12.032","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stereochemistry of phase-1 metabolites of mephedrone determines their effectiveness as releasers at the serotonin transporter","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2018.12.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}